Peptides Research Hub

Clinical Trial Identifier

NCT03552757

Semaglutide 2.4 mg subcutaneous, part of the STEP program.

Trial details

Identifier
NCT03552757
Sponsor
Novo Nordisk
Asset
Semaglutide 2.4 mg subcutaneous
Program
STEP
Phase
Phase III
Therapeutic area
Obesity / Weight Management

Program context

STEP

STEP-1 reported approximately 14.9% mean body-weight reduction at 68 weeks versus 2.4% with placebo. STEP-3 (with intensive behavioral therapy) achieved approximately 16.0% weight reduction. STEP-8 showed significantly greater weight loss with semaglutide 2.4 mg than with liraglutide 3.0 mg. Reimbursement and access vary substantially by country.

Read the STEP spotlight

Trial-level analysis lives in the program spotlight linked above. For the canonical registry record, including study design, eligibility, locations, and posted results, visit ClinicalTrials.gov.